Butterfield, Lisa H.

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology

Sarcoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 1,452

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

Tarhini, A. A., Zahoor, H., Lin, Y., Malhotra, U., Sander, C., Butterfield, L. H., & Kirkwood, J. M. (2015) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 394

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Padrón, L. J., Maurer, D. M., O’Hara, M. H., O’Reilly, E. M., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G., Rahma, O., Lyman, J. P., et al. (2022) · Nature Medicine

Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers

Cited by 384

Web‐based collaborative care intervention to manage cancer‐related symptoms in the palliative care setting

Steel, J. L., Geller, D. A., Kim, K. H., Butterfield, L. H., Spring, M., Grady, J., Sun, W., Marsh, W., Antoni, M., Dew, M. A., et al. (2016) · Cancer

Cancer survivorship and carePalliative Care and End-of-Life Issues

Cited by 116

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma

Retseck, J., Nasr, A., Lin, Y., Lin, H., Mendiratta, P., Butterfield, L. H., & Tarhini, A. A. (2018) · Journal of Translational Medicine

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 51